Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

Introduction Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2017-02, Vol.34 (2), p.513-523
Hauptverfasser:	Breul, Jürgen, Lundström, Eija, Purcea, Daniela, Venetz, Werner P., Cabri, Patrick, Dutailly, Pascale, Goldfischer, Evan R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - pharmacology Biological Availability Cardiology Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - pharmacology Endocrinology Gonadotropin-Releasing Hormone - agonists Health technology assessment Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Oncology Original Research Pharmacology/Toxicology Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Retrospective Studies Rheumatology Testosterone - blood Treatment Outcome Triptorelin Pamoate - administration & dosage Triptorelin Pamoate - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to
ISSN:	0741-238X 1865-8652
DOI:	10.1007/s12325-016-0466-7